Induction therapy with cetuximab plus docetaxel, cisplatin, and 5‐fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO‐07 study. (14th February 2015)

• Record Type: Journal Article
• Authors: Chibaudel, Benoist; Lacave, Roger; Lefevre, Marine; Soussan, Patrick; Antoine, Martine; Périé, Sophie; Belloc, Jean‐Baptiste; Banal, Alain; Albert, Sébastien; Chabolle, Frédéric; Céruse, Philippe; Baril, Philippe; Gatineau, Michel; Housset, Martin; Moukoko, Rachel; Benetkiewicz, Magdalena; de Gramont, Aimery; Bonnetain, Franck; Lacau St Guily, Jean
• Is Part Of: Cancer medicine. Volume 4:Number 5(2015:May)
• Page Start: 721
• Page End: 731
• Publication Date: 2015-02-14
• Subjects: 616.994005
• DOI: 10.1002/cam4.408
• Languages: English
• ISSNs: 2045-7634

Abstract

<abstract abstract-type="graphical" xml:lang="en" id="cam4408-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p>This phase II study reports a clinical and radiological complete response of 22% and a primary tumor overall response rate of 58% for ETPF in patients with moderately advanced squamous cell carcinoma of the oropharynx. The schedule of ETPF evaluated in this study cannot be recommended at this dosage. <graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgjmx2c2hj" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></p> </abstract>